Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
Stakeholder Letter Supporting Joint Resolutions to Overturn FDA Rule on LDTs
-
ACMG Response to Senate HELP Committee RFI on Diagnostics Regulation
-
Sign-on Letter Opposing the Patent Eligibility Restoraction Act of 2024
-
Sign-on Letter Asking Congress to Make Medicare Telehealth Waivers Permanent
-
ACMG Response to RFI on Gene Therapies Access for Rare Diseases
-
Sign-on Letter to Congress Urging Reversal of 2024 Physician Payment Cuts
-
ACMG Comments on FDA Proposed Rule for Regulation of LDTs
-
Sign-on Letter Asking Congress to Pass Legislation to Stop Pending Physician Payment Cuts
-
Stakeholder Letter Asking Congress Renew Efforts on CLIA Reform and Urge FDA to Halt LDT Rulemaking